I'm A Patient
I'm A Provider
Direct Answer
No device currently holds regulatory authorization specifically for halting the structural progression of dry age-related macular degeneration (AMD). This is an honest and important starting point for any clinical conversation on this topic. The intervention with the strongest published evidence for reducing progression risk is not a device at all: it is AREDS2 nutritional supplementation, which reduces the risk of progression to advanced AMD by approximately 25% in eligible patients.1
What has changed in recent years is the availability of authorized device-based therapy for a different, but equally important clinical goal: improving visual function in eligible dry AMD patients. This is a distinct aim from slowing structural progression, and understanding that distinction is essential for setting accurate patient expectations and making sound clinical decisions.2
The Structural vs. Functional Distinction in Dry AMD Management
Dry AMD affects patients in two overlapping but separable ways. The first is structural: the progressive degeneration of retinal pigment epithelium cells, the accumulation of drusen and, in advanced cases, the development of geographic atrophy. These changes can be tracked with optical coherence tomography (OCT) imaging over time. The second is functional: the impact of that structural damage on the patient’s ability to see in daily life, measured by visual acuity and contrast sensitivity.3
Progression management addresses the structural dimension. The goal is to reduce the rate at which drusen accumulate, geographic atrophy expands, or disease advances to the stage of vision-threatening choroidal neovascularisation. AREDS2 supplementation has evidence for reducing this structural risk in intermediate and advanced dry AMD. No currently Health Canada–authorized treatment device has been shown in a clinical trial to slow structural AMD progression.1
Functional improvement addresses the second dimension. The goal is to improve how well the patient sees now, regardless of what the structural picture shows. A patient may have significant drusen burden or areas of early atrophy on OCT but retain meaningful visual acuity and contrast sensitivity. Improving those functional measures has a direct impact on quality of life and daily independence. This is the domain where Health Canada–authorized device-based therapy has demonstrated clinical benefit.2
Clinicians and patients who conflate these two goals can end up with misaligned expectations. A patient who receives device-based therapy hoping to stop their AMD from progressing structurally may be disappointed even if their visual acuity improves meaningfully. Conversely, a patient focused solely on structural progression risk may overlook a functional improvement opportunity available to them now.
What Currently Addresses Dry AMD Progression Risk?
AREDS2 Supplementation
The AREDS2 formula, a combination of lutein, zeaxanthin, vitamin C, vitamin E, and zinc, is the most robustly evidenced intervention for reducing the risk of structural progression in dry AMD. The Age-Related Eye Disease Study 2, a large randomized trial funded by the US National Eye Institute, found that AREDS2 supplementation reduced the risk of progression to advanced AMD by approximately 25% in patients with intermediate dry AMD or advanced disease in one eye.1
AREDS2 supplements are widely available and do not require a device or clinical procedure. Their appropriate use requires confirmation of AMD stage by an eye care professional, as they are not indicated for early dry AMD and carry specific formulation considerations. In particular, versions containing beta-carotene are contraindicated in current or former smokers due to elevated lung cancer risk. A clinician should review the patient’s eligibility and recommend an appropriate formulation before supplementation begins.1
AREDS2 supplementation does not improve visual acuity or contrast sensitivity. Its benefit is in structural risk reduction, not functional improvement. It is most appropriately understood as a risk modifier rather than a treatment for visual symptoms.
Lifestyle Modification
Several lifestyle factors are associated with the risk of AMD progression and are often within patients’ control. Stopping smoking is the most impactful modifiable risk factor: smokers face substantially higher rates of AMD progression than non-smokers. Diet quality, UV protection for the eyes, cardiovascular health management, and physical activity have also been associated with AMD risk in epidemiological research.3
These modifications carry no clinical risk and are appropriate at every stage of dry AMD. They do not constitute treatment in a clinical sense but are a meaningful component of a comprehensive management plan.
Monitoring
Regular retinal imaging with OCT is essential for tracking structural change over time. It is not a treatment for progression, but is the mechanism by which structural change is detected early enough to respond appropriately. In particular, monitoring enables prompt identification of conversion from dry to wet AMD. Wet AMD requires urgent anti-VEGF treatment and follows a different disease course from dry AMD.3
What Currently Addresses Dry AMD Functional Decline?
Authorized Device-Based Therapy
For patients whose concern is not only what will happen to their AMD structurally, but what can be done about their vision now, authorized device-based therapy offers a clinically supported option. MacuMira is a Health Canada–authorized treatment device indicated to improve visual function in patients with dry AMD. It is not indicated for slowing progression and does not make that claim.2
In MacuMira’s published randomized sham-controlled clinical trial, the treatment group showed statistically significant improvement in both visual acuity and contrast sensitivity over the treatment period. The average gain was 8.2 letters on the ETDRS scale, with 48% of treated patients gaining 10 or more letters. Contrast sensitivity improved by an average of 0.24 log units. Zero device-related serious adverse events were recorded in the trial or across more than 21,000 treatments in 3 countries since launch.2
MacuMira is not indicated for wet AMD. The published trial enrolled patients with visual acuity between 20/50 and 20/200. Patients with better baseline acuity may experience a ceiling effect that limits the measurable scope for improvement. A clinical assessment, including confirmation of AMD stage and baseline visual acuity measurement, is required to determine eligibility.2
Treatment typically consists of four 32-minute sessions delivered over 10 days (patients should budget about one hour in-office per visit), followed by routine maintenance appointments every 10–12 weeks. This ongoing maintenance schedule should be communicated clearly to patients before treatment begins.2
Low Vision Rehabilitation
For patients with significant existing vision loss from dry AMD, low vision rehabilitation addresses the functional consequences of what has already occurred. Low vision specialists work with patients to maximize the use of remaining vision through magnification devices, adaptive lighting, contrast-enhancement strategies, and practical training for everyday tasks. This does not affect AMD progression or visual acuity in the conventional clinical sense, but can substantially improve daily independence and quality of life.3
Why the Search for a Progression-Slowing Device Matters
The question of whether a clinical device can slow the progression of dry AMD reflects genuine and reasonable clinical interest. Structural progression, particularly the expansion of geographic atrophy, causes cumulative and irreversible damage to the macula. Slowing that process would be a meaningful clinical benefit, and it is the focus of considerable ongoing research.4
Several investigational approaches are in clinical development that target complement pathway activity, retinal pigment epithelium cell health, and other aspects of AMD biology. Some early data is promising. However, none of these approaches has yet achieved regulatory authorization for a progression-slowing claim in dry AMD at the time of writing. Clinicians should monitor the published literature and regulatory announcements for developments in this area, as the landscape may change.4
In the meantime, the most honest and helpful clinical position is to clearly distinguish between what is available now for structural progression risk reduction (AREDS2 and lifestyle modification), what is available for functional improvement (authorized device-based therapy) and what remains investigational.
How to Discuss This Distinction with Patients
Many patients who ask about slowing AMD progression are motivated by a desire to take action and to feel that something is being done about their condition. That motivation is valid and should be respected. The clinical task is to redirect it toward the actions that are actually supported by evidence.
A useful framing is to separate the two goals explicitly. Something like: “We have two goals in managing your dry AMD. The first is to reduce the risk of your disease progressing structurally, and for that we have AREDS2 supplements and lifestyle changes. The second is to see whether we can improve how well you see now, and for that there is now an authorized therapy we can discuss.” This framing is accurate and positive, and it gives patients a concrete set of options to engage with.
Patients who ask specifically about devices to slow progression should be told clearly that no device currently has that regulatory authorization, that the search for one is active, and that new options may become available in the future. Honesty on this point builds trust and avoids the disappointment of unmet expectations.
Questions Clinicians and Patients Should Consider
- What is the patient’s current AMD stage and are they eligible for AREDS2 supplementation?1
- Is the patient’s current visual acuity within the range for device-based functional improvement therapy?2
- What is the patient’s primary concern: the risk of structural deterioration or the quality of their current visual function?
- Are there lifestyle modifications the patient has not yet adopted that would reduce their structural progression risk?
- Is the patient aware that no device is currently authorized for slowing dry AMD progression and that the available device-based therapy addresses visual function rather than structural course?2
- What is the monitoring schedule and how will structural changes be tracked alongside any functional improvement from device-based therapy?3
Key takeaway
No device currently holds regulatory authorization for slowing dry AMD structural progression. The best-evidenced intervention for reducing progression risk is AREDS2 supplementation, not a device. What has become available in clinics is Health Canada–authorized therapy to improve visual function in eligible dry AMD patients.
MacuMira is indicated for this purpose and is supported by a published randomized, sham-controlled trial demonstrating statistically significant improvements in visual acuity and contrast sensitivity in the treatment group, with no device-related serious adverse events across more than 21,000 real-world treatments. It is not indicated for slowing progression or for wet AMD. A complete dry AMD management plan addresses both structural risk, through supplementation and lifestyle and functional improvement, through authorized device-based therapy where the patient is eligible.
Disclaimer
This article is for informational and educational purposes only. It does not constitute medical advice or a clinical recommendation. Patients and clinicians should consult current regulatory guidance and published clinical evidence when making treatment decisions.
Glossary
Structural progression: Changes in the physical structure of the macula over time in dry AMD, including drusen accumulation and geographic atrophy expansion. Distinct from functional decline.
Functional improvement: Measurable gains in how well a patient sees, assessed through ETDRS visual acuity and contrast sensitivity. The authorized indication for device-based dry AMD therapy.
AREDS2 formula: A nutritional supplement combination shown to reduce the risk of progression to advanced AMD by approximately 25% in eligible patients. Addresses structural risk, not visual function improvement.
Geographic atrophy: An advanced stage of dry AMD in which large areas of retinal pigment epithelium and photoreceptors have degenerated irreversibly.
MacuMira: A Health Canada–authorized medical device indicated to improve visual function in patients with dry AMD, delivered via low-level electrical stimulation in a clinical setting under the supervision of a licensed eye care professional. Not indicated for slowing AMD progression or for wet AMD.
ETDRS scale: The Early Treatment Diabetic Retinopathy Study visual acuity scale, scored letter by letter. The standard outcome measure in AMD clinical trials.
Contrast sensitivity: The ability to distinguish objects from their background at varying contrast levels. Frequently reduced in dry AMD independently of high-contrast visual acuity.
Ceiling effect: In clinical measurement, the limited scope for improvement when a patient’s baseline function is near the upper end of the measurement scale.
Dry AMD: A progressive retinal condition affecting the macula. The most common form of AMD. Distinct from wet AMD.
Wet AMD: A form of AMD involving abnormal blood vessel growth beneath the retina. Treated with anti-VEGF injections. Requires urgent treatment. MacuMira is not indicated for wet AMD.
Sham-controlled trial: A clinical trial design in which the control group receives a procedure mimicking the active intervention except for the active component. The appropriate design for device efficacy trials.
References
1. Lutein + Zeaxanthin and Omega-3 Fatty Acids for Age-Related Macular Degeneration: The Age-Related Eye Disease Study 2 (AREDS2) Randomized Clinical Trial. AREDS2 Research Group. JAMA. Published May 15, 2013. Accessed June 2026. https://jamanetwork.com/journals/jama/fullarticle/1684847.
2. Evaluation of visual acuity in dry AMD patients after microcurrent electrical stimulation. Parkinson KM, Sayre EC, Tobe SW. International Journal of Retina and Vitreous. Published May 2023. Accessed June 2026. https://macumira.com/wp-content/uploads/2025/07/MacuMira-Clinical-Trial.pdf.
3. Age-Related Macular Degeneration. National Eye Institute, National Institutes of Health. Last reviewed November 2023. Accessed June 2026. https://www.nei.nih.gov/eye-health-information/eye-conditions-and-diseases/age-related-macular-degeneration.
4. Understanding Macular Degeneration. American Academy of Ophthalmology. Published November 2025. Accessed June 2026. https://www.aao.org/eye-health/diseases/amd-macular-degeneration.
5. Age-Related Macular Degeneration (AMD). Canadian Ophthalmological Society. Date not listed. Accessed June 2026. https://www.seethepossibilities.ca/eye-health/age-related-macular-degeneration/.
